Erratum to: Nucl Med Mol Imaging
10.1007/s13139-014-0314-0
Owing to an oversight by the authors, the following information was omitted from this article:
Funding Development of the 18F-choline PET/CT imaging procedure described in this report was supported by U.S. National Institutes of Health National Cancer Institute grant R21CA139687-2. The Queen’s Medical Center also received payments from Bayer Healthcare Pharmaceuticals, Inc. to evaluate this procedure in patients receiving radium-223 dichloride.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at http://dx.doi.org/10.1007/s13139-014-0314-0.
Rights and permissions
About this article
Cite this article
Miyazaki, K.S., Kuang, Y. & Kwee, S.A. Erratum to: Changes in Skeletal Tumor Activity on 18F-choline PET/CT in Patients Receiving 223Radium Radionuclide Therapy for Metastatic Prostate Cancer. Nucl Med Mol Imaging 49, 335 (2015). https://doi.org/10.1007/s13139-015-0329-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13139-015-0329-1